Older Americans screened for cancer despite limited benefits
the ONA take:
According to a new report in The Journal of the American Medical Association Internal Medicine, up to 50% of older people in the United States received cancer screening despite a high probability that they would die without cancer within the next 9 years. Trevor Royce, MD, MS, of the University of North Carolina at Chapel Hill and his colleagues agree that routine cancer screenings has minimal benefits for patients with a limited life expectancy.
In the study, the researchers assessed responses from 27,404 people at least 65 years old. Based on their responses, the researchers estimated their probability of death within the next 9 years and then identified which of those had recently been screened for breast, cervical, colon, and prostate cancers.
They found that 55% of men who had a 75% risk of death had received a prostate specific antigen (PSA) screening. Approximately 33% of women with a 75% risk of death received breast and cervical cancer screenings. In addition, 41% of people who were not likely to live another 10 years received colon cancer screenings.
The American Cancer Society and other professional societies recommend stopping PSA screening in men who are not expected to live another 10 years.
Despite potential risks, many are still screened for cancers toward the end of their lives.
Up to half of older people in the U.S. received cancer screenings even though there was a high likelihood that they would die within nine years without cancer, researchers report in JAMA Internal Medicine.
“There is general agreement that routine cancer screening has little likelihood to result in a net benefit for individuals with limited life expectancy,” write Dr. Trevor Royce and his fellow researchers from the University of North Carolina, Chapel Hill. Several professional societies have updated their cancer screening guidelines to suggest that people who aren't expected to live another 10 years should not be screened for certain cancers.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|